Worldwide, the total incidence of cutaneous melanoma is higher in men than in women, with
some differences related to ethnicity and age and, above all, sex and gender. Differences …

More recently, disease metastasis and relapse in many cancer patients several years (even
some decades) after surgical remission are regarded as tumor dormancy. However, the …

Metastasis and relapse account for the great majority of cancer-related deaths. Most
metastatic lesions are micro metastases that have the capacity to remain in a non-dividing …

Background Most metastatic melanoma patients treated with BRAF inhibitors (BRAFi)±MEK
inhibitors (MEKi) eventually progress on treatment. Along with acquired resistance due to …

Disseminated tumor cells (DTCs) are recognized as the seeds of metastasis. However,
metastatic lesions can become symptomatic years or decades after primary tumor removal …

Background Sesquiterpene lactones having α-methylene-γ-lactone moiety are promising
natural metabolites showing various biological activity. One of the major metabolites isolated …

Metastatic spread in breast cancer patients is the major driver of cancer-related deaths. A
unique subset of cells disseminated from pre-invasive or primary tumor lesions are …

Melanoma is one of the most lethal neoplasms of the skin. Despite the revolutionary
introduction of immune checkpoint inhibitors, metastatic spread, and recurrence remain …

Quiescent state has been observed in stem cells (SCs), including in adult SCs and in cancer
SCs (CSCs). Quiescent status of SCs contributes to SC self-renewal and conduces to …

Vemurafenib, an oral BRAF inhibitor, has demonstrated high response rates in
relapsed/refractory (R/R) hairy cell leukemia (HCL). However, little is known about long-term …